However, biologics targeting IL-17 or IL-23 have emerged as an important treatment option for psoriasis and have led to a substantial improvement in the QOL of patients owing to their superior effect on decreasing subjective disease burden compared with conventional therapies [7]. Here, IL17A is linked to psoriasis.